Femasys Inc. (NASDAQ:FEMY) Sees Significant Growth in Short Interest

Femasys Inc. (NASDAQ:FEMY) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 526,700 shares, an increase of 6.0% from the October 15th total of 496,900 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily trading volume, of 150,300 shares, the days-to-cover ratio is currently 3.5 days.

Hedge Funds Weigh In On Femasys

Several large investors have recently made changes to their positions in FEMY. Geode Capital Management LLC raised its position in Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after purchasing an additional 17,473 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the period. Aljian Capital Management LLC acquired a new stake in Femasys in the third quarter valued at $27,000. Finally, CM Management LLC raised its position in shares of Femasys by 6.3% during the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after purchasing an additional 25,000 shares during the last quarter. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Stock Performance

Shares of NASDAQ:FEMY traded down $0.05 during midday trading on Tuesday, reaching $0.88. 204,340 shares of the company’s stock traded hands, compared to its average volume of 331,961. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. Femasys has a 1 year low of $0.73 and a 1 year high of $2.40. The company has a fifty day simple moving average of $1.15 and a two-hundred day simple moving average of $1.14.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The firm had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts forecast that Femasys will post -0.84 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on FEMY shares. Chardan Capital lowered their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Femasys in a report on Tuesday, November 12th.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.